KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Short term Debt: 2011-2020

  • Nektar Therapeutics' Short term Debt was N/A to $254.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $254.1 million, marking a year-over-year change of. This contributed to the annual value of $252.9 million for FY2019, which is N/A change from last year.
  • Latest data reveals that Nektar Therapeutics reported Short term Debt of $254.1 million as of Q1 2020, which was up 0.50% from $252.9 million recorded in Q4 2019.
  • Over the past 5 years, Nektar Therapeutics' Short term Debt peaked at $254.1 million during Q1 2020, and registered a low of $252.9 million during Q4 2019.
  • For the 2-year period, Nektar Therapeutics' Short term Debt averaged around $253.5 million, with its median value being $253.5 million (2019).